This site is intended for healthcare professionals

Phase III trial of Covaxin meets primary endpoint in COVID-19 phase III study.- Ocugen/Bharat Biotech

Read time: 1 mins
Last updated:29th Jul 2021
Published:5th Jul 2021
Ocugen announced that its co-development partner, Bharat Biotech, shared positive results of its Phase III study of Covaxin, a whole virion inactivated COVID-19 vaccine candidate.
Condition: Coronavirus/COVID-19 Infection
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest